An Exclusive Charitable Partnership
As breakthroughs in cancer immunotherapy are happening today, it is important to remember that they are due in large part to basic research that has been going on for decades. While we are very proud to support the public companies that are bringing these therapies to patients today, we also view it as our obligation to support the early stage private research that will lead to breakthroughs of tomorrow.
With that in mind, Loncar Investments has entered into an exclusive charitable partnership for the Loncar Cancer Immunotherapy ETF (CNCR) with the Cancer Research Institute (CRI).
CRI is the leader in backing immunotherapy research, and so it is our honor to support them. Loncar Investments will use royalties it receives as the exchange-traded fund’s index provider to donate regular contributions to CRI that amount to 4 basis points, or 0.04%, of CNCR’s total assets.
“Today’s breakthroughs in cancer immunotherapy have emerged from decades of basic scientific research funded by visionary benefactors, with the Cancer Research Institute at the forefront. As our index supports public companies delivering these advances to patients, we want to foster that critical early research as well. There is no better way to do that than to give to an immunotherapy pioneer like CRI.”
– Brad Loncar,
CEO, Loncar Investments
The partnership is a two-year agreement, with an option for renewal in 2017. Loncar Investments has guaranteed a minimum donation of at least $20,000 per calendar year.